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Introduction: Atopic dermatitis (AD) is the most
common skin disorder in young children worldwide,
with a high impact on morbidity and quality of life. To
date, no prospective study has been published on the
incidence and potential predictors of AD in South East
Asian populations. The Indonesian Prospective Study
of Atopic Dermatitis in Infants (ISADI) will address the
genetic, metabolic and dietary characteristics of
mothers and their offspring, as well as potential
determinants of AD within the first year of infant life.
Methods and analysis: This prospective study will
be undertaken in about 400 infants to investigate the
direct and indirect effects of filaggrin (FLG) gene
mutations, the genetic variants of FADS1, FADS2 and
FADS3 and the role of long-chain polyunsaturated fatty
acids (LCPUFA) on the development of AD. We will use
standardised protocols for subject recruitment,
umbilical artery plasma analysis, buccal cell sampling
for genotyping, fatty acid analysis, physical exams, 3-
day food-intake recall of mothers and children, as well
as comprehensive questionnaires on environmental,
socioeconomic and AD-related factors, including family
history. Monthly monitoring by telephone and physical
exams every 3 months will be carried out to assess
participants’ anthropometry, medical history and
incidence of AD diagnosis during the first year of life.
Hypotheses-driven analyses of quality-controlled
dietary, genetic and metabolic data will be performed
with state-of-the-art statistical methods (eg, AD-event
history, haplotype, dietary or metabolic factor analysis).
Direct and indirect effects of genetics and LCPUFA in
buccal cell and cord plasma glycerophospholipids as
potential mediators of inflammation on AD
development will be evaluated by path analysis.
Ethics and dissemination: The Permanent Medical
Research Ethics Committee in Medicine and Health/
Faculty of Medicine Universitas Indonesia/Dr Cipto
Mangunkusumo Hospital (No. 47/H2.F1/ETIK/2014)
approved the study protocol (extended by the letter no.
148/UN2.F1/ETIK/2015). We aim to disseminate our
findings via publication in an international journal with
high impact factor.
BACKGROUND
The incidence and prevalence of atopic
dermatitis (AD) have increased markedly in
recent years, possibly due to interactions
between genetic and environmental factors.
At least 20 genes are reportedly related to
AD, but one genetic locus has been consist-
ently linked with AD occurrence, the filag-
grin (FLG) gene.1 2 Mutation of the gene
causes loss of function and disturbances in
Strengths and limitations of this study
▪ This study is the first in Asia to evaluate the role
of FADS genes on long-chain polyunsaturated
fatty acid (LCPUFA) compositions in buccal cells
and plasma.
▪ This study is the first in Asia to evaluate the
roles of FADS genes and LCPUFA concentrations
on the progression of AD.
▪ We hypothesise that in utero exposure to
LCPUFA provides greater benefits to infants com-
pared to exposure in infancy or childhood. As
such, we will sample participants’ umbilical
artery plasma in order to assess actual fetal con-
ditions, rather than umbilical vein plasma, as
performed in other studies.
▪ Diagnosis of AD will be based on Hanifin &
Rajka criteria and confirmed by a dermatologist.
▪ We will assess for filaggrin mutations by single
nucleotide polymorphism (SNP) analysis of five
reported pathogenic SNPs. However, full gene
sequencing would be more accurate, as the filag-
grin (FLG) gene varies according to population.
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epidermal cytoskeleton aggregation, thereby increasing
skin permeability to water and outside particles, such as
allergens.1 3
Much effort has been made to prevent AD, such as
promotion of exclusively breastfeeding for at least
3 months, reduction of allergen exposure such as to dust
mites and tobacco, using partially hydrolysed formula for
infants unable to breastfeed, probiotic supplementation,
restoration of the skin barrier and supplementation with
long-chain polyunsaturated fatty acids (LCPUFA).1 4–7
From the omega-3 LCPUFA eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) and the
omega-6 LCPUFA arachidonic acid (ARA) prostaglandins
(PG), leukotrienes (LT) and thromboxanes (TX) are
synthesised.8–15 To date, clinical trials and meta-analyses
have shown inconsistent results. Studies in the past
5–10 years showed that polymorphisms in the gene
encoding fatty acid desaturases (FADS genes) influence
the contribution of polyunsaturated fatty acids (PUFA)
and LCPUFA, which are derived by desaturation and
chain elongation from PUFA, to total lipids.11–13 16–19
To date, there have been no studies in Indonesia on
FLG gene mutations, the composition of LCPUFAs in
infants, FADS1 and FADS2 gene polymorphisms, nor on
possible associations of these gene polymorphisms.
These data are needed, considering the large size of the
Indonesian population (fourth largest in the world with
a population of 237 641 326 people), consisting of 1128
tribes.20 The results of this study are expected to provide
information about the interaction of genetic variation,
nutrition and the progression of AD in infants.
AIMS AND OBJECTIVES
The general objective of this study is to characterise the
impact of genetic variation in the FLG gene and the
FADS1, FADS2 and FADS3 gene cluster on LCPUFA in
plasma and buccal cell lipids, as well as the occurrence
and severity of AD in Indonesian infants. Specific objec-
tives include the characterisation of the frequency of
FLG and FADS1, FADS2 and FADS3 gene single nucleo-
tide polymorphisms (SNPs) assessed in umbilical artery
leucocytes, the fatty acid composition of umbilical artery
plasma and buccal cell lipids and the impact of FLG
gene and FADS1, FADS2 and FADS3 gene SNPs, LCPUFA
status, maternal diet and breastfeeding on AD in the
first year of life in Indonesian infants.
ATOPIC DERMATITIS
AD (also commonly known as atopic eczema) is a
chronic skin disorder characterised by inflammation and
itching. It is one of the most common disorders found
in children with a high impact on morbidity and quality
of life. It often precedes the occurrences of allergic rhin-
itis and asthma, which has been referred to as the
‘atopic march’.21–23 The worldwide prevalence of AD
has increased during the past three decades, and
currently 10–20% of children are affected.1 24–26 AD
often begins in very early childhood, with as many as
45% of all cases reported to be manifested in the first
6 months of life.1 21–25
Several approaches have been explored for AD preven-
tion, such as reducing exposure to common environ-
mental allergens such as house dust mites, tobacco and
cows’ milk protein, probiotic supplementation, restor-
ation of skin barrier and LCPUFA supplementation.26–28
However, no prospective study on the incidence and
potential predictors of AD in Southeast Asian popula-
tions has been published.25
FILAGGRIN GENE
SNPs of the filaggrin gene (FLG, access number in
GenBank NM_002016) have been described as a major
etiologic factor of keratinisation disorders, including ichthy-
osis vulgaris and AD, in Western populations.26 The filag-
grin gene is located on the 1q21 chromosome in an area
called the epidermal differentiation complex (EDC). The
EDC is involved in the formation of the stratum corneum,
the outermost layer of skin which acts as a barrier.26
Sequencing of exon 3 is challenging because of its size
and the repetitions between units 10 and 12. So far,
some 49 mutations in the FLG gene have been reported,
all of which are missense and frameshift mutations.27 28
Genetic analyses in Asian populations have shown very
different results from European populations. The
R501X (Arg501Stop) and 2282del4 mutations are most
commonly found in European populations. In Asian
populations, more commonly found mutations are
3321delA in China and Korea; 441delA, 1249insG,
7945delA, Q2147X, E2422X and R4307X in
Chinese-Singaporeans; R501X and 3321delA mutations
in Japan; R501X and 2282del4 in Pakistan and E1795X
in Taiwan.29–36 Hence, FLG gene mutation screening is
challenging in Asian AD patients. More knowledge is
needed on the distribution of FLG mutations in different
Asian populations, including people from Indonesia.
LONG-CHAIN POLYUNSATURATED FATTY ACIDS
EPA, DHA and ARA have a major impact on human
health outcomes, such as motor and cognitive develop-
ment, mental health and psychiatric disorders, cardiovas-
cular disorders and immunologic and inflammatory
responses.8 10 LCPUFA are essential components of all
plasma membranes, modulate transcription and act in
cellular signalling pathways through their eicosanoid,
docosanoid and resolvin metabolites.37
Inflammatory cells usually contain relatively large
amounts of ARA and several other LCPUFA. ARA is a
substrate for the synthesis of PG, TX, LT and other oxi-
dative derivatives formed by cyclooxygenase (COX) and
lipoxygenase (LOX) activity in inflammatory and epithe-
lial cells.38 39
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FATTY ACID DESATURASE (FADS) GENE AND ITS
RELATIONSHIP TO AD
The FADS1, FADS2 and FADS3 gene cluster is located on
chromosome 11q12–q13.1 and has a size of 91.9 kb.40 A
first candidate gene study published in 2006 in Germany
demonstrated that SNPs in the FADS1 and FADS2 genes
are predictive of the conversion of precursor PUFA to
LCPUFA, as well as the risk of allergic response.11
Participants with minor alleles had higher plasma PUFA
precursor concentrations and a lower product/substrate
ratio, indicative of reduced desaturase activity. These
findings were subsequently replicated in many other
populations.12 13 41–44
In several studies, the FADS gene location in chromo-
some 11q12–11q13.1 has been linked with atopy. In a
German birth cohort, a significant association between
FADS SNPs and the risk of AD was found, while in a
Dutch birth cohort study no such association was found,
potentially related to different assessment methods for
AD in the two studies and a higher habitual fish intake
(providing n−3 LCPUFA) in the Dutch population.43
Further insights in the association of FADS SNPs and
PUFA status with AD might be gained by replication
studies in populations with different living conditions,
such as in Indonesian infants.
METHODS
Study area and population
The study will be performed in a Primary Healthcare
facility in Kemayoran District, Central Jakarta, for
18 months. Participants are apparently healthy newborn
infants born full term (37–42 weeks of gestation), whose
parents agreed to be included in the study by providing
written informed consent.
Inclusion and exclusion criteria
Inclusion criteria:
1. Newborns: full term, healthy, birth weight more than
2500 g and no major congenital anomaly.
2. Mothers: agree to take part in the study and sign the
informed consent.
3. Mothers with normal gestational history and without
complications such as gestational hypertension and
gestational diabetes mellitus, and not vegetarian.
4. Mothers without severe illness during or after labour.
5. Mothers who did not take omega-3 and omega-6 sup-
plementation during pregnancy and breastfeeding.
Exclusion criteria:
Newborns who received omega-3 or omega-6 supple-
mentation in syrup/caplet form.
Study design
In this prospective birth cohort, we use two research
designs, cross-sectional and longitudinal (survival analysis).
The cross-sectional design will be used to look for
associations between FADS1, FADS2 and FADS3 SNPs and
PUFA composition at birth in umbilical artery plasma
glycerophospholipids and in buccal swab cell glyceropho-
spholipids.45 46 For the first time, data on genetic variants
in the FLG gene and the FADS gene cluster, as well as
PUFA levels, will be available for Indonesian neonates.
Moreover, the relationship between genetic make-up and
PUFA levels will be explored by regression methods. In
addition, the association of the FLG gene and FADS1,
FADS2 and FADS3 SNPs with the emergence of AD in the
first year of life will be assessed. We will consider dietary
PUFA intake and neonatal PUFA status as covariates by
standard logistic regression methods,47 as well as by survival
analysis approaches to account for the differences in obser-
vation times and censoring due to incident AD, disease-
free time over the study period or lost to follow-up.48
The longitudinal design will be used to assess average
time and differences in incident AD development
among groups of infants with different genotypes, PUFA
cord plasma glycerphospholipid levels. These analyses
will account for covariates such as family history of atopy
and infants’ diet and will be assessed over the first year
of life by a survival analysis approach.48 49 Thus, this pro-
spective design will also allow us to disentangle the rela-
tive contributions of genetic and nutritional aspects, as
will statistical path analyses to test for a potential mediat-
ing effect of PUFA levels among genotypes and AD
development.50
Ethical aspects
Participants in this study will be treated in accordance
with the Declaration of Helsinki. Ethical review was per-
formed by The Permanent Medical Research Ethics
Committee in Medicine and Health/Faculty of Medicine
Universitas Indonesia/Dr Cipto Mangunkusumo
Hospital no. 47/H2.F1/ETIK/2014 and extended by the
letter no. 148/UN2.F1/ETIK/2015.
Sample size calculation
We will use a consecutive sampling procedure to collect
participants.
The number of participants was calculated using the
formula of proportion comparison sample size between
two unpaired groups.51









N is the sample size;
Zα is the alpha raw deviate of 5%, Zα value is 1.96;
Zβ is the beta raw deviate=0.84;
P2 is the atopic dermatitis proportion in minor allele
(MiA)=0.06;




On the basis of the calculations using the above
formula, the minimum required number of participants
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for each group is 152 newborns. Taking into consider-
ation a 10% loss to follow-up, a minimum of 335 partici-
pants are needed. A good power of the study will be
achieved if the minimum major allele to minor allele
ratio is 3:1, which would result in at least 90 participants
in the minor allele group.
Procedures
Briefly, FLG gene mutation and FADS1, FADS2 and
FADS3 gene polymorphisms will be examined from the
buffy coat of umbilical artery and LCPUFA level will be
measured in plasma of umbilical artery and in buccal
cells in about 400 newborns from a Primary Healthcare
Centre in Kemayoran District.
Umbilical artery blood specimens will be collected dir-
ectly after birth and put into EDTA tubes. Buccal cells
will be collected from infants within 1 hour of birth by
brushing the surfaces of the inner mouth mucosa 20–25
times with gentle pressure, using a Gynobrush (Herenz
1032929). The brush is then put into a Sarstedt tube
(62.554.502—15 mL). The brush is held in place by the
tube cap, so that the cells stuck to the brush will sedi-
ment on centrifugation. Centrifugation will be per-
formed at 1400×g for 10 min at 4°C, the supernatant
removed and the tube stored at −80°C. A second buccal
specimen will be obtained from the infants at the age of
12 months or at the time when AD is diagnosed.
Specimens will be immediately frozen at −80°C and
transported by air to Ludwig-Maximilians-Universität
München on dry ice where they will be stored at −80°C
until analysis.
Questionnaire data consisting of parental age, parity,
address, educational level, family income, ethnicity,
atopic history of parents and blood siblings, number of
siblings, problems in pregnancy, smoking history in preg-
nancy and maternal exposure to nicotine during preg-
nancy will be recorded by investigators. Monthly
monitoring by telephone will be performed to collect
information on breastfeeding, duration of exclusive/pre-
dominant or any breastfeeding, formula feeding includ-
ing type and amount of formula given and any other
food provided. At the time when complementary
feeding starts, 3-day food-intake recalls will be obtained
from mothers and infants and evaluated by
NUTRISURVEY (http://www.nutrisurvey.de). Infants will
undergo examinations at 3, 6, 9 and 12 months of age at
the study centre, including medical history, physical
examination and possible diagnosis of AD based on
Hanifin & Rajka criteria.
In addition, at any time parents report the presence
of skin disorders or a suspicion of AD, the infant will be
invited to Pantai Indah Kapuk Hospital for assessment
by a skilled dermatologist. If the infant is unable to visit
the hospital, a home visit will be performed and photo-
graphs of the skin lesion will be subsequently evaluated
by an experienced dermatologist.
LCPUFA analysis from buccal cell lipids will be per-
formed after methanol-based ultrasound facilitated lipid
extraction. Specimen preparation and gas chromatog-
raphy (Model 7890 gas chromatograph; Agilent,
Darmstadt, Germany) will be performed as described
previously.46 Fatty acid results will be reported in per-
centage of total fatty acids analysed (mol%). In this ana-
lysis, nine PUFA values will be included, namely linoleic
acid (LA/C18:2n−6), γ-linolenic acid (GLA/C18:3n−6),
dihomo-γ-linolenic acid (DGLA/C20:3n−6), arachidonic
acid (ARA/C20:4n−6), adrenic acid (A/C22:4n−6),
α-linolenic acid (ALA/C18:3n−3), eicosapentaenoic acid
(EPA/C20:5n−3), docosapentaenoic acid (DPA/C22:5n
−3) and docosahexaenoic acid (DHA/C22:6n−3).
FLG gene mutation and FADS1, FADS2 and FADS3 gene
polymorphism analysis
DNA will be extracted from the buffy coat of the umbil-
ical artery by the Puregene DNA isolation kit (Gentra
Systems, http://www.gentra.com). Genotyping will be
performed using iPLEX Gold Chemistry (Sequenom)
and matrix-assisted laser desorption ionisation-time of
flight (MALDI-TOF) mass spectrometry, with methods
to detect allelic differences, as previously described.16 In
brief, locations containing certain SNPs will be amplified
by PCR using specific primers. After deactivation by alka-
line phosphatase, single base elongation will be per-
formed. In this reaction, primary elongation is
performed in accordance to the print order. After salt
ion removal by ion switch and elongation reaction, the
specimen will be transferred to silicone chip and
covered with 3-hydroxypicolinic acid. The differences
from specific alleles will be measured by MALDI-TOF.
Allele recognition from SNPs will be performed by Mass
ARRAY Typer V.4.0.5 (Sequenom). We plan to assess 18
SNPs for the FADS1, FADS2 and FADS3 genes and five
SNPs for the FLG gene.27 44
SNPs for FADS genes were selected based on three cri-
teria: (1) the SNP has been studied in previous publica-
tions; (2) the SNP candidates in consideration are SNPs
that have already been shown to be associated with
LC-PUFA status or AD and (3) minor allele frequency is
>10%.11
Since FLG gene SNPs in Indonesian populations have
not been reported and this gene varies among popula-
tions, the SNPs were selected based on the National
Centre of Biotechnology Information (NCBI) reporting
of pathogenic SNPs, which were rs61816761 (for
R501X), rs797045090 (Q715X), rs121909626 (S2554X),
rs74129447 (R3858H) and rs558269137 (2282del4).52–58
IDENTIFICATION OF THE VARIABLE
For cross-sectional study design:
The dependent variables are PUFA percentage con-
tents in buccal cells and plasma glycerophospholipids,
namely LA (C18: 2n−6), GLA (C18:3n−6), DGLA
(C20:3n−6), ARA (C20:4n−6), A (C22:4n−6), ALA
(C18:3n−3), EPA (C20:5n−3), DPA (C22:5n−3) and
DHA (C22:6n−3).
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The independent variables are 18 SNPs of the FADS
gene, namely rs174548, rs174556, rs174561, rs3834458,
rs968567, rs174570, rs174574, rs2727271, rs174576,
rs174578, rs174579, rs174602, rs498793, rs526126,
rs174575, rs174448, rs174449 and rs174455.
For prospective study design:
The dependent variable is AD, while independent
variables are:
▸ 18 SNPs of the FADS1, FADS2 and FADS3 genes,
namely rs174548, rs174556, rs174561, rs3834458,
rs968567, rs174570, rs174574, rs2727271, rs174576,
rs174578, rs174579, rs174602, rs498793, rs526126,
rs174575, rs174448, rs174449 and rs174455.
▸ PUFA contents: LA (C18: 2n−6), GLA (C18:3n−6),
DGLA (C20:3n−6), AA (C20:4n−6), A (C22:4n−6),
ALA (C18:3n−3), EPA (C20:5n−3), DPA (C22:5n−3)
and DHA (C22:6n−3) in plasma and buccal cell
glycerophospholipids.
▸ 5 SNPs of the FLG gene mutation, namely
rs61816761, rs797045090, rs121909626, rs74129447
and rs558269137.
DISSEMINATION
We aim at dissemination of findings via publication in
an international journal with high impact factor.
PLAN OF DATA PROCESSING, ANALYSIS AND
PRESENTATION
All data processing will be performed with SAS 9.4 or R
3.2.4 (http://www.r-project.org). Allele frequency,
Hardy–Weinberg equilibrium (HWE), linkage disequilib-
rium (LD) and further measures will be assessed with
R-package Genetics (https://cran.r-project.org/web/
packages/genetics/). The latter will be calculated by
Fisher’s exact test. The LD test for each pair of SNP
locus will be tested with Lewontin’s D. In addition,
paired correlation r2 in the study population will be cal-
culated. Normal distribution of fatty acid will be assessed
by the Kolmogorov–Smirnov test, box plots and QQ
plots. Haplotype analysis will be performed to evaluate
for association of the genetic profile and more than one
SNP at a time with AD (https://cran.r-project.org/web/
packages/haplo.stats/index.html). The results of this
study will be disseminated in a high impact journal.
Logistic regression will be performed to evaluate the
effect of each SNP and concentration of each fatty acid on
the development of AD that arises in the first year of life.47
Incidence of AD will be estimated by survival analysis, using
Kaplan–Meier product limit estimates to assess mean sur-
vival times for various groups and to depict disease-free
and event times within the first year of life. Differences in
survival curves among groups will be tested by log-rank
tests48 49 The specific survival analysis model of
Cox-proportional hazard regression will be applied to allow
multiple adjustments, covariates and potential predictors.49
Direct and indirect effects of genetic and nutrition
(including maternal diet) on AD with PUFA in buccal
cells and plasma glycerophospholipids as a potential
mediator will be evaluated by moderated mediation path
analysis.50
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